Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 236

1.

Characterization of cefotaxime-resistant urinary Escherichia coli from primary care in South-West England 2017-18.

Findlay J, Gould VC, North P, Bowker KE, Williams MO, MacGowan AP, Avison MB.

J Antimicrob Chemother. 2019 Sep 20. pii: dkz397. doi: 10.1093/jac/dkz397. [Epub ahead of print]

PMID:
31538190
2.

Pharmacodynamics of plazomicin and a comparator aminoglycoside, amikacin, studied in an in vitro pharmacokinetic model of infection.

Noel AR, Attwood M, Bowker KE, Kim A, Krause KM, MacGowan AP.

Int J Antimicrob Agents. 2019 Jul 9. pii: S0924-8579(19)30181-5. doi: 10.1016/j.ijantimicag.2019.07.001. [Epub ahead of print]

PMID:
31299297
3.

Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures.

Noel AR, Bowker KE, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2019 Jul 1;74(7):1945-1951. doi: 10.1093/jac/dkz114.

PMID:
31220257
4.

Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?-authors' response.

Russell AH, Horner C, Livermore DM, MacGowan AP.

J Antimicrob Chemother. 2019 Jun 1;74(6):1767. doi: 10.1093/jac/dkz105. No abstract available.

PMID:
30915460
5.

An in vitro biofilm model of Staphylococcus aureus infection of bone.

Sweeney E, Lovering AM, Bowker KE, MacGowan AP, Nelson SM.

Lett Appl Microbiol. 2019 Apr;68(4):294-302. doi: 10.1111/lam.13131. Epub 2019 Mar 13.

PMID:
30770577
6.

Optimizing the Design and Analysis of Clinical Trials for Antibacterials Against Multidrug-resistant Organisms: A White Paper From COMBACTE's STAT-Net.

de Kraker MEA, Sommer H, de Velde F, Gravestock I, Weiss E, McAleenan A, Nikolakopoulos S, Amit O, Ashton T, Beyersmann J, Held L, Lovering AM, MacGowan AP, Mouton JW, Timsit JF, Wilson D, Wolkewitz M, Bettiol E, Dane A, Harbarth S; COMBACTE-NET Consortium.

Clin Infect Dis. 2018 Nov 28;67(12):1922-1931. doi: 10.1093/cid/ciy516.

7.

Doxycycline in UK guidelines for hospital-acquired pneumonia: where is the evidence base?

Russell AH, Horner C, Livermore DM, MacGowan AP.

J Antimicrob Chemother. 2018 Nov 1;73(11):3212-3215. doi: 10.1093/jac/dky306. No abstract available.

PMID:
30085229
8.

Antibacterial effect of ceftolozane/tazobactam in combination with amikacin against aerobic Gram-negative bacilli studied in an in vitro pharmacokinetic model of infection.

Noel AR, Bowker KE, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2018 Sep 1;73(9):2411-2417. doi: 10.1093/jac/dky225.

PMID:
30020472
9.

Pharmacodynamics of inhaled amikacin (BAY 41-6551) studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, Tomaselli S, Attwood M, MacGowan AP.

J Antimicrob Chemother. 2018 May 1;73(5):1305-1313. doi: 10.1093/jac/dky002.

PMID:
29562340
10.

Prediction of Fluoroquinolone Susceptibility Directly from Whole-Genome Sequence Data by Using Liquid Chromatography-Tandem Mass Spectrometry To Identify Mutant Genotypes.

Wan Nur Ismah WAK, Takebayashi Y, Findlay J, Heesom KJ, Jiménez-Castellanos JC, Zhang J, Graham L, Bowker K, Williams OM, MacGowan AP, Avison MB.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01814-17. doi: 10.1128/AAC.01814-17. Print 2018 Mar.

11.

Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection.

Alfouzan WA, Noel AR, Bowker KE, Attwood MLG, Tomaselli SG, MacGowan AP.

Int J Antimicrob Agents. 2017 Dec;50(6):715-717. doi: 10.1016/j.ijantimicag.2017.06.026. Epub 2017 Jul 10.

PMID:
28705678
12.

Towards better antimicrobial susceptibility testing: impact of the Journal of Antimicrobial Chemotherapy.

Wootton M, MacGowan AP, Howe RA.

J Antimicrob Chemother. 2017 Feb;72(2):323-329. doi: 10.1093/jac/dkw494. Review.

PMID:
28115501
13.

A review of the pharmacokinetics and pharmacodynamics of aztreonam.

Ramsey C, MacGowan AP.

J Antimicrob Chemother. 2016 Oct;71(10):2704-12. doi: 10.1093/jac/dkw231. Epub 2016 Jun 21. Review.

PMID:
27334663
14.

Early warning score: a dynamic marker of severity and prognosis in patients with Gram-negative bacteraemia and sepsis.

Albur M, Hamilton F, MacGowan AP.

Ann Clin Microbiol Antimicrob. 2016 Apr 12;15:23. doi: 10.1186/s12941-016-0139-z.

15.

Differences in the pharmacodynamics of ceftaroline against different species of Enterobacteriaceae studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, Tomaselli S, MacGowan AP.

J Antimicrob Chemother. 2016 May;71(5):1270-8. doi: 10.1093/jac/dkv480. Epub 2016 Feb 3.

PMID:
26846209
16.

Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.

MacGowan AP, Noel AR, Tomaselli SG, Nicholls D, Bowker KE.

Antimicrob Agents Chemother. 2015 Nov 9;60(1):515-21. doi: 10.1128/AAC.00727-15. Print 2016 Jan.

17.

A non-fatal case of hantavirus cardiopulmonary syndrome imported into the UK (ex Panama), July 2014.

Atkinson B, Jameson LJ, Bovill BA, Aarons EJ, Clewlow J, Lumley S, Latham J, Jenkins MH, MacGowan AP, Simpson AJ, Ahmed J, Brooks TJ, Hewson R.

J Clin Virol. 2015 Jun;67:52-5. doi: 10.1016/j.jcv.2015.04.007. Epub 2015 Apr 8. No abstract available.

18.

Ceftaroline in the management of complicated skin and soft tissue infections and community acquired pneumonia.

Mpenge MA, MacGowan AP.

Ther Clin Risk Manag. 2015 Apr 7;11:565-79. doi: 10.2147/TCRM.S75412. eCollection 2015. Review.

19.

In memoriam: William A. Craig.

Theuretzbacher U, Ambrose PG, MacGowan AP, Andes DR, Sörgel F, Derendorf H, Mouton JW, Drusano GL, Tulkens PM, Dudley MN, Cars O, Nation RL.

Antimicrob Agents Chemother. 2015;59(6):2971. doi: 10.1128/AAC.00849-15. Epub 2015 Apr 20. No abstract available.

20.

Prevalence of antibiotic resistance in Escherichia coli isolated from urine samples routinely referred by general practitioners in a large urban centre in south-west England.

Chin TL, MacGowan AP, Bowker KE, Elder F, Beck CR, McNulty C.

J Antimicrob Chemother. 2015 Jul;70(7):2167-9. doi: 10.1093/jac/dkv050. Epub 2015 Mar 11. No abstract available.

PMID:
25766735
21.

Viral infections in pregnancy: advice for healthcare workers.

Chin TL, MacGowan AP, Jacobson SK, Donati M.

J Hosp Infect. 2014 May;87(1):11-24. doi: 10.1016/j.jhin.2013.12.011. Epub 2014 Mar 12. Review.

PMID:
24767811
22.

Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07--authors' response.

Reynolds R, Hope R, Warner M, MacGowan AP, Livermore DM, Ellington MJ; BSAC Extended Working Party on Resistance Surveillance.

J Antimicrob Chemother. 2013 Jul;68(7):1693-4. doi: 10.1093/jac/dkt119. Epub 2013 Apr 4. No abstract available.

PMID:
23557922
23.

Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Bowker KE.

Antimicrob Agents Chemother. 2013 Jun;57(6):2451-6. doi: 10.1128/AAC.01386-12. Epub 2013 Mar 4.

24.

Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum.

Bowker KE, Garvey MI, Noel AR, Tomaselli SG, Macgowan AP.

J Antimicrob Chemother. 2013 May;68(5):1130-8. doi: 10.1093/jac/dks537. Epub 2013 Jan 29.

PMID:
23361641
25.

Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07.

Reynolds R, Hope R, Warner M, MacGowan AP, Livermore DM, Ellington MJ; BSAC Extended Working Party on Resistance Surveillance.

J Antimicrob Chemother. 2012 Dec;67(12):2912-8. doi: 10.1093/jac/dks324. Epub 2012 Aug 16.

PMID:
22899805
26.

Pharmacodynamics of the antibacterial effect of and emergence of resistance to doripenem in Pseudomonas aeruginosa and Acinetobacter baumannii in an in vitro pharmacokinetic model.

Bowker KE, Noel AR, Tomaselli SG, Elliott H, Macgowan AP.

Antimicrob Agents Chemother. 2012 Oct;56(10):5009-15. doi: 10.1128/AAC.06111-11. Epub 2012 Jun 19.

27.

The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach.

Mouton JW, Brown DF, Apfalter P, Cantón R, Giske CG, Ivanova M, MacGowan AP, Rodloff A, Soussy CJ, Steinbakk M, Kahlmeter G.

Clin Microbiol Infect. 2012 Mar;18(3):E37-45. doi: 10.1111/j.1469-0691.2011.03752.x. Epub 2012 Jan 20. Review.

28.

EUCAST expert rules in antimicrobial susceptibility testing.

Leclercq R, Cantón R, Brown DF, Giske CG, Heisig P, MacGowan AP, Mouton JW, Nordmann P, Rodloff AC, Rossolini GM, Soussy CJ, Steinbakk M, Winstanley TG, Kahlmeter G.

Clin Microbiol Infect. 2013 Feb;19(2):141-60. doi: 10.1111/j.1469-0691.2011.03703.x. Epub 2011 Nov 25. Review.

29.

Role of early intravenous to oral antibiotic switch therapy in the management of prosthetic hip infection treated with one- or two-stage replacement.

Darley ES, Bannister GC, Blom AW, Macgowan AP, Jacobson SK, Alfouzan W.

J Antimicrob Chemother. 2011 Oct;66(10):2405-8. doi: 10.1093/jac/dkr277. Epub 2011 Jul 8.

PMID:
21742678
30.

Pharmacodynamics of razupenem (PZ601) studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel A, Tomaselli S, Elliott H, Bowker K.

Antimicrob Agents Chemother. 2011 Apr;55(4):1436-42. doi: 10.1128/AAC.00936-10. Epub 2011 Jan 24.

31.

Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.

MacGowan AP, Noel AR, Tomaselli S, Elliott HC, Bowker KE.

Antimicrob Agents Chemother. 2011 Feb;55(2):867-73. doi: 10.1128/AAC.00933-10. Epub 2010 Nov 15.

32.
33.

Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service.

Tobin CM, Lovering AM, Sweeney E, MacGowan AP.

J Antimicrob Chemother. 2010 Oct;65(10):2155-7. doi: 10.1093/jac/dkq266. Epub 2010 Aug 3.

PMID:
20682566
34.

Bacterial strain-to-strain variation in pharmacodynamic index magnitude, a hitherto unconsidered factor in establishing antibiotic clinical breakpoints.

MacGowan AP, Reynolds R, Noel AR, Bowker KE.

Antimicrob Agents Chemother. 2009 Dec;53(12):5181-4. doi: 10.1128/AAC.00118-09. Epub 2009 Oct 5.

35.

Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.

Bowker KE, Noel AR, MacGowan AP.

J Antimicrob Chemother. 2009 Nov;64(5):1044-51. doi: 10.1093/jac/dkp289. Epub 2009 Sep 16.

PMID:
19759041
36.

In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.

Bowker KE, Caspers P, Gaucher B, MacGowan AP.

Antimicrob Agents Chemother. 2009 Nov;53(11):4949-52. doi: 10.1128/AAC.00845-09. Epub 2009 Sep 8.

37.

Clinical implications of antimicrobial resistance for therapy.

Macgowan AP; BSAC Working Parties on Resistance Surveillance.

J Antimicrob Chemother. 2008 Nov;62 Suppl 2:ii105-14. doi: 10.1093/jac/dkn357. Review.

PMID:
18819975
38.

An HPLC assay for daptomycin in serum.

Tobin CM, Darville JM, Lovering AM, Macgowan AP.

J Antimicrob Chemother. 2008 Dec;62(6):1462-3. doi: 10.1093/jac/dkn414. Epub 2008 Sep 28. No abstract available.

PMID:
18824457
39.

Tigecycline pharmacokinetic/pharmacodynamic update.

MacGowan AP.

J Antimicrob Chemother. 2008 Sep;62 Suppl 1:i11-6. doi: 10.1093/jac/dkn242. Review. Erratum in: J Antimicrob Chemother. 2010 Jul;65(7):1549.

PMID:
18684702
40.

Pharmacodynamics of minocycline against Staphylococcus aureus in an in vitro pharmacokinetic model.

Bowker KE, Noel AR, Macgowan AP.

Antimicrob Agents Chemother. 2008 Dec;52(12):4370-3. doi: 10.1128/AAC.00922-07. Epub 2008 Jun 2.

41.
43.

Occurrence and current frequency of CTX-M-type beta-lactamases from a regional hospital in the South West of England.

Tarrant F, MacGowan AP, Walsh TR.

J Antimicrob Chemother. 2007 Apr;59(4):815-6. Epub 2007 Feb 8. No abstract available.

PMID:
17289761
44.
45.

Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory.

Soltani M, Tobin CM, Bowker KE, Sunderland J, MacGowan AP, Lovering AM.

Int J Antimicrob Agents. 2006 Dec;28(6):574-7. Epub 2006 Nov 7.

PMID:
17085019
46.
47.

Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system.

Bowker KE, Noel AR, MacGowan AP.

J Antimicrob Chemother. 2006 Oct;58(4):802-5. Epub 2006 Aug 5.

PMID:
16891629
48.

European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing.

Kahlmeter G, Brown DF, Goldstein FW, MacGowan AP, Mouton JW, Odenholt I, Rodloff A, Soussy CJ, Steinbakk M, Soriano F, Stetsiouk O.

Clin Microbiol Infect. 2006 Jun;12(6):501-3.

49.

Assay of ertapenem in human serum by high-performance liquid chromatography.

Soltani M, MacGowan AP, Lovering AM.

Int J Antimicrob Agents. 2006 Feb;27(2):165-7. Epub 2006 Jan 18.

PMID:
16417992
50.

Expression of tcaA and mprF and glycopeptide resistance in clinical glycopeptide-intermediate Staphylococcus aureus (GISA) and heteroGISA strains.

Wootton M, Macgowan AP, Walsh TR.

Biochim Biophys Acta. 2005 Nov 30;1726(3):326-7. Epub 2005 Sep 22.

PMID:
16213099

Supplemental Content

Loading ...
Support Center